Vcaps® Enteric Capsule Technology
Vcaps® Enteric is a fully compliant capsule technology that simplifies drug enteric delivery implementation from early stage development to commercial manufacturing. Vcaps Enteric capsules have been evaluated in-vitro and in-vivo across a number of compounds, and have proven full compliance with relevant EP, JP and US Pharmacopeia monographs. By removing the need for enteric coating, Vcaps® Enteric capsules offer tremendous potential in early stage product development, greatly simplifying formulation and process development as well as scale-up and validation. Intrinsically enteric capsule technologies also provide product differentiation and life cycle management opportunities.
Contact Details:
Company name: Capsugel
Website: www.capsugel.com/biopharmaceutical-products/vcaps-enteric-capsules
E-mail: solutions.emea@capsugel.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
